{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:12:55Z","timestamp":1789056775242,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003081","name":"Ministry of Education, Ethiopia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003654","name":"Korea Environmental Industry and Technology Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003562","name":"Korea Ministry of Environment","doi-asserted-by":"publisher","award":["RS-2025\\u201302223058"],"award-info":[{"award-number":["RS-2025\\u201302223058"]}],"id":[{"id":"10.13039\/501100003562","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119237","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:46:13Z","timestamp":1773920773000},"page":"119237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Phenotypic profiles for anticancer drug responses using tumor spheroids"],"prefix":"10.1016","volume":"198","author":[{"given":"Youngwon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiseok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2809-9113","authenticated-orcid":false,"given":"Bongseop","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2026.119237_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119237_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1489094","article-title":"Drug repurposing and phenotypic screening: Innovative strategies for treating ultra-rare disorders","volume":"11","author":"Paquot","year":"2024","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119237_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.chembiol.2021.01.010","article-title":"The future of phenotypic drug discovery","volume":"28","author":"Berg","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"5977","key":"10.1016\/j.biopha.2026.119237_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1126\/science.1189015","article-title":"Genotype to phenotype: a complex problem","volume":"328","author":"Dowell","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.biopha.2026.119237_bib6","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1128\/MCB.24.15.6837-6849.2004","article-title":"Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents","volume":"24","author":"Francia","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"13","key":"10.1016\/j.biopha.2026.119237_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/86.13.975","article-title":"Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents","volume":"86","author":"Graham","year":"1994","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.biopha.2026.119237_bib8","article-title":"Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions","volume":"1866","author":"Azadi","year":"2019","journal-title":"Biochim. Et. Biophys. ActaMol. Cell Res."},{"issue":"8","key":"10.1016\/j.biopha.2026.119237_bib9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.biotechadv.2016.11.002","article-title":"3D tumor spheroids: an overview on the tools and techniques used for their analysis","volume":"34","author":"Costa","year":"2016","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib10","article-title":"Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations","volume":"13","author":"Abbas","year":"2023","journal-title":"Sci. Rep. Uk"},{"issue":"3","key":"10.1016\/j.biopha.2026.119237_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nprot.2008.226","article-title":"Spheroid-based drug screen: considerations and practical approach","volume":"4","author":"Friedrich","year":"2009","journal-title":"Nat. Protoc."},{"issue":"13","key":"10.1016\/j.biopha.2026.119237_bib12","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1039\/D4LC00249K","article-title":"Parathyroid-on-a-chip simulating parathyroid hormone secretion in response to calcium concentration","volume":"24","author":"Lee","year":"2024","journal-title":"Lab a Chip"},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/bit.26845","article-title":"3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs","volume":"116","author":"Nunes","year":"2019","journal-title":"Biotechnol. Bioeng."},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01853-8","article-title":"Challenges of applying multicellular tumor spheroids in preclinical phase","volume":"21","author":"Han","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","article-title":"Cellpose: a generalist algorithm for cellular segmentation","volume":"18","author":"Stringer","year":"2021","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s13206-024-00143-5","article-title":"Optimization of tumor spheroid preparation and morphological analysis for drug evaluation","volume":"18","author":"Lee","year":"2024","journal-title":"Biochip J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s13206-022-00086-9","article-title":"Fabrication of cell spheroids for 3D cell culture and biomedical applications","volume":"17","author":"Park","year":"2023","journal-title":"BioChip J."},{"key":"10.1016\/j.biopha.2026.119237_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2018.02.029","article-title":"Mass fabrication of uniform sized 3D tumor spheroid using high-throughput microfluidic system","volume":"275","author":"Kwak","year":"2018","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biopha.2026.119237_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119237_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1010662413174","article-title":"Determinants of paclitaxel uptake, accumulation and retention in solid tumors","volume":"19","author":"Jang","year":"2001","journal-title":"Investig. N. Drugs"},{"issue":"10","key":"10.1016\/j.biopha.2026.119237_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1349-7006.1994.tb02906.x","article-title":"Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion","volume":"85","author":"Tamura","year":"1994","journal-title":"Jpn. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119237_bib22","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/bjc.2014.137","article-title":"A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours","volume":"110","author":"Eskens","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119237_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-7-197","article-title":"Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy","volume":"7","author":"Fr Brunsvig","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2026.119237_bib24","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.2147\/DDDT.S251144","article-title":"Analysis of the doxorubicin and doxorubicinol in the plasma of breast cancer patients for monitoring the toxicity of doxorubicin","author":"Harahap","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.biopha.2026.119237_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","author":"Mart\u00edn","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119237_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1067\/mcp.2000.109352","article-title":"Dose and time dependencies of 5-fluorouracil pharmacokinetics","volume":"68","author":"Terret","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119237_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1932-3","article-title":"Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report","volume":"15","author":"Yang","year":"2015","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2026.119237_bib28","first-page":"2723","article-title":"Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial","volume":"47","author":"Struck","year":"1987","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119237_bib29","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5026","article-title":"Proteasome inhibitors decrease paclitaxel-induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1\/cyclin B1","volume":"48","author":"Hu","year":"2021","journal-title":"Int J. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119237_bib30","article-title":"The effect of paclitaxel on apoptosis, autophagy and mitotic catastrophe in AGS cells","volume":"11","author":"Khing","year":"2021","journal-title":"Sci. Rep. Uk"},{"issue":"4","key":"10.1016\/j.biopha.2026.119237_bib31","first-page":"86","article-title":"Breaking malignant nuclei as a non-mitotic mechanism of taxol\/paclitaxel","volume":"2","author":"Smith","year":"2021","journal-title":"J. Cancer Biol."},{"key":"10.1016\/j.biopha.2026.119237_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10103-009-0723-y","article-title":"Apoptosis-and necrosis-induced changes in light attenuation measured by optical coherence tomography","volume":"25","author":"van der Meer","year":"2010","journal-title":"Lasers Med. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119237_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4161\/cbt.10.3.12207","article-title":"NADPH oxidase 4 is an oncoprotein localized to mitochondria","volume":"10","author":"Graham","year":"2010","journal-title":"Cancer Biol. & Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119237_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.biopha.2026.119237_bib35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","article-title":"Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over","volume":"18","author":"Paridaens","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119237_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1008370930599","article-title":"Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere\u00ae) in the UK","volume":"10","author":"O'Brien","year":"1999","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119237_bib37","first-page":"1062","article-title":"A ten-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times","volume":"29","author":"Ansfield","year":"1969","journal-title":"Cancer Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226002702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:28:39Z","timestamp":1779244119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226002702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["S0753332226002702"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119237","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic profiles for anticancer drug responses using tumor spheroids","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119237"}}